CCR6 inhibitor 1 is primarily used in research and therapeutic contexts targeting inflammatory and autoimmune diseases. It works by blocking the CCR6 receptor, which is involved in the migration of immune cells, particularly Th17 cells, to sites of inflammation. This makes it a potential candidate for treating conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Additionally, it is being explored for its role in cancer immunotherapy, as CCR6 signaling is implicated in tumor microenvironments and metastasis. Its application in preclinical studies helps in understanding immune cell trafficking and developing targeted therapies for chronic inflammatory disorders.